Evidence map›Paper›PMID 31998804›Full record

SynthesisBioMed research international2020

Population Pharmacokinetics of Clozapine: A Systematic Review.

Orwa Albitar, Sabariah Noor Harun, Hadzliana Zainal, Baharudin Ibrahim, Siti Maisharah Sheikh Ghadzi

Open access · hybridAbstract readSystematic Review
In one paragraph

Synthesis in BioMed research international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.

  1. Guideline
  2. Review
  3. Article
  4. Article
  5. Differences in clozapine metabolism across geographical regions in Turkiye.Dusunen adam : Bakirkoy Ruh ve Sinir Hastaliklari Hastanesi yayin organi · 2025
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Clozapine use at a specialised psychiatric hospital in Johannesburg.The South African journal of psychiatry : SAJP : the journal of the Society of Psychiatrists of South Africa · 2023
    Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Orwa AlbitarSchool of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 USM, George Town, Penang, Malaysia.ORCID https://orcid.org/0000-0003-4676-1334
Sabariah Noor HarunSchool of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 USM, George Town, Penang, Malaysia.ORCID https://orcid.org/0000-0001-8476-7425
Hadzliana ZainalSchool of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 USM, George Town, Penang, Malaysia.
Baharudin IbrahimSchool of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 USM, George Town, Penang, Malaysia.ORCID https://orcid.org/0000-0001-8534-2517
Siti Maisharah Sheikh GhadziSchool of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 USM, George Town, Penang, Malaysia.ORCID https://orcid.org/0000-0001-8855-8954
Universiti Sains Malaysia · MY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveClozapine is a second-generation antipsychotic drug that is considered the most effective treatment for refractory schizophrenia. Several clozapine population pharmacokinetic models have been introduced in the last decades. Thus, a systematic review was performed (i) to compare published pharmacokinetics models and (ii) to summarize and explore identified covariates influencing the clozapine pharmacokinetics models.

methodsA search of publications for population pharmacokinetic analyses of clozapine either in healthy volunteers or patients from inception to April 2019 was conducted in PubMed and SCOPUS databases. Reviews, methodology articles, in vitro and animal studies, and noncompartmental analysis were excluded.

resultsTwelve studies were included in this review. Clozapine pharmacokinetics was described as one-compartment with first-order absorption and elimination in most of the studies. Significant interindividual variations of clozapine pharmacokinetic parameters were found in most of the included studies. Age, sex, smoking status, and cytochrome P450 1A2 were found to be the most common identified covariates affecting these parameters. External validation was only performed in one study to determine the predictive performance of the models.

conclusionsLarge pharmacokinetic variability remains despite the inclusion of several covariates. This can be improved by including other potential factors such as genetic polymorphisms, metabolic factors, and significant drug-drug interactions in a well-designed population pharmacokinetic model in the future, taking into account the incorporation of larger sample size and more stringent sampling strategy. External validation should also be performed to the previously published models to compare their predictive performances.

Indexed as

Antipsychotic AgentsClozapineModels, BiologicalSchizophreniaAdultCytochrome P-450 CYP1A2FemaleHumansMaleMiddle AgedAntipsychotic AgentsClozapineCYP1A2 protein, humanCytochrome P-450 CYP1A2

Identifiers

PMID31998804
PMCPMC6970501
OpenAlexW2999008070

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.